Gamco Investors INC. ET AL Purchases 295,139 Shares of Pfizer Inc. (NYSE:PFE)

Gamco Investors INC. ET AL lifted its position in Pfizer Inc. (NYSE:PFE) by 123.9% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 533,251 shares of the biopharmaceutical company’s stock after buying an additional 295,139 shares during the period. Gamco Investors INC. ET AL’s holdings in Pfizer were worth $14,798,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. Creekmur Asset Management LLC acquired a new position in shares of Pfizer in the 4th quarter valued at approximately $32,000. Trivant Custom Portfolio Group LLC boosted its holdings in shares of Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 600 shares during the period. Tennessee Valley Asset Management Partners bought a new stake in shares of Pfizer during the fourth quarter worth $36,000. DiNuzzo Private Wealth Inc. bought a new stake in Pfizer in the 4th quarter valued at $37,000. Finally, ESL Trust Services LLC bought a new stake in Pfizer in the 1st quarter valued at $37,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on PFE. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price target (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Barclays lifted their target price on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday, July 10th. Finally, Morgan Stanley lifted their price objective on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Nine investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $34.50.

Pfizer Stock Performance

NYSE PFE traded up $1.00 during trading on Friday, reaching $30.77. 35,657,080 shares of the company’s stock were exchanged, compared to its average volume of 30,301,530. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $37.19. The business has a 50 day moving average price of $28.54 and a 200-day moving average price of $27.77. The stock has a market capitalization of $174.36 billion, a P/E ratio of -512.75, a PEG ratio of 1.18 and a beta of 0.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.26. The business had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company’s quarterly revenue was down 19.5% on a year-over-year basis. During the same quarter last year, the firm posted $1.23 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 5.46%. The ex-dividend date is Friday, July 26th. Pfizer’s dividend payout ratio is -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.